Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Bayer takes on Astellas in purchase of experimental menopause relief

08/11/2020 | 05:46am EST

Bayer moved to acquire a prospective non-hormonal menopause relief for an initial $425 million to strengthen its women's healthcare business, in a challenge to a similar development venture at Astellas.

Under the deal to buy KaNDy Therapeutics Ltd. from a group of investment firms, Bayer also agreed to pay up to $450 million (344 million pounds) for certain development achievements, with potentially more than $100 million additional sales-dependent payments, the German company said in a statement on Tuesday.

KaNDy in January announced positive data from the second of three phases of testing for NT-814, a new non-hormonal daily pill to ease hot flushes and night sweats, which Bayer said could generate peak annual sales of more then 1 billion euros (899 million pounds).

It is behind Japan's Astellas, which a year ago started the third phase of testing of a similar compound known as fezolinetant. NT-814, in turn, would address a wider range of symptoms, the head of Bayer's drugs division Stefan Oelrich told Reuters.

Bayer is seeking to revive its women's healthcare business as cheaper copied versions have lowered its sales of birth control pills.

It is close to settling injury claims over inserted birth control device Essure for more than 1 billion euros.

"We are one of the leaders in the area of women's health... resulting in synergies on many levels, starting with product development, but also commercialisation," Oelrich said.

Previous moves to reinvigorate the franchise include an alliance with Evotec to develop a treatment for a common cause of infertility in women.

Bayer's pharma unit, which in 2018 changed its strategy to increase its reliance on external sources of innovation, would not rule out future transactions larger than the KaNDy deal, Oelrich told Reuters.

But he cautioned that late-stage projects came at "very, very high prices".

By Ludwig Burger


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. 2.08% 1720 End-of-day quote.7.90%
BAYER AG 0.50% 50.31 Delayed Quote.4.02%
EVOTEC SE 2.04% 36.99 Delayed Quote.19.52%
All news about ASTELLAS PHARMA INC.
04:51aASTELLAS PHARMA INC. : - Result of Open Innovation Challenge 'Astellas Rx+ Healt..
AQ
01/25ASTELLAS PHARMA : Builds New Manufacturing Lines for Aseptic Drugs at Yaizu Tech..
MT
01/25ASTELLAS PHARMA INC. : - Establishing New Manufacturing Lines for Aseptic Drug P..
AQ
01/25Japanese shares gain tracking U.S. futures; tech and pharma stocks boost
RE
01/24Japanese shares track U.S. futures higher, tech leads gains
RE
01/14ACTINIUM PHARMACEUTICALS : and Astellas Announce Research Collaboration Focused ..
AQ
01/06ASTELLAS PHARMA INC. : - FDA Accepts for Priority Review the New Drug Applicatio..
AQ
2020ASTELLAS PHARMA : FDA Lifts Clinical Hold for Audentes Therapeutics' AT132 Trial
MT
2020ASTELLAS PHARMA : Reports XOSPATA in Combination with Azacitidine Did Not Meet E..
AQ
2020ASTELLAS PHARMA : Supports Recommendations of Task Force on Climate-related Fina..
AQ
More news
Financials
Sales 2021 1 269 B 12 149 M 12 149 M
Net income 2021 177 B 1 692 M 1 692 M
Net cash 2021 441 B 4 224 M 4 224 M
P/E ratio 2021 17,7x
Yield 2021 2,41%
Capitalization 3 172 B 30 476 M 30 359 M
EV / Sales 2021 2,15x
EV / Sales 2022 1,97x
Nbr of Employees 15 883
Free-Float 99,2%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 2 229,17 JPY
Last Close Price 1 740,50 JPY
Spread / Highest target 107%
Spread / Average Target 28,1%
Spread / Lowest Target -5,20%
EPS Revisions
Managers and Directors
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.7.90%31 065
JOHNSON & JOHNSON6.67%441 951
ROCHE HOLDING AG3.62%309 011
NOVARTIS AG0.20%212 810
PFIZER INC.-1.55%201 436
MERCK & CO., INC.-5.78%194 990